Pony.ai wins first permit for fully driverless taxi operation in the center of China’s Silicon Valley

Pony.ai wins first permit for fully driverless taxi operation in the center of China’s Silicon Valley


Key Points
  • In the latest step towards building a revenue-generating robotaxi business, Chinese startup Pony.ai said it has obtained the first permit to charge fares for fully driverless taxis in core parts of a business district of Shenzhen.
  • The permit allows Pony.ai to charge fares for rides — without any human staff inside — from the Shenzhen international airport and Shenzhen Bay Port to key parts of the district of Nanshan, home to tech giants Tencent and DJI.
  • While Pony.ai did not disclose how many robotaxis it could operate in the region, the company said the driverless cars could run daily from 7:30 a.m. to 10 p.m. local time.



Source

Here are 3 forces that drove the stock market during Wall Street’s comeback week
Finance

Here are 3 forces that drove the stock market during Wall Street’s comeback week

The stock market staged a comeback last week, even as Wall Street waded through a flurry of both upbeat and unsettling headlines. The Nasdaq broke its five-week losing streak on Friday, buoyed by strong advances from our big tech names like Meta Platforms , Nvidia and Amazon . The tech-heavy index ended the week 1.9% […]

Read More
Market volatility trap? Why this income-first strategy may ‘leave a lot on the table’
Finance

Market volatility trap? Why this income-first strategy may ‘leave a lot on the table’

ETF Edge Market volatility trap? Why this income-first strategy may ‘leave a lot on the table’ Published Sat, Feb 21 202611:00 AM EST Blair Bao WATCH LIVE Source

Read More
Stocks making the biggest moves premarket: Grail, Blue Owl Capital, Opendoor Technologies & more
Finance

Stocks making the biggest moves premarket: Grail, Blue Owl Capital, Opendoor Technologies & more

Check out the companies making headlines before the bell. Grail — Shares cratered 47% after the company said a trial of one of its drugs missed its primary endpoint and failed to show statistically significant Stage III-IV cancer reduction. Blue Owl Capital — Shares slid nearly 3%, a day after after the private market and […]

Read More